scholarly journals Adrenal gland as a target of synchronous and metacronous metastasis from renal cell carcinoma: results of surgical treatment in a single institution

2020 ◽  
Vol 15 (4) ◽  
pp. 50-57
Author(s):  
A. G. Muradyan ◽  
A. A. Kostin ◽  
N. V. Vorobyev ◽  
A. O. Tolkachev
Keyword(s):  
Renal Cell Carcinoma ◽  
Surgical Treatment ◽  
Adrenal Gland ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Lesion Group ◽  
Adrenal Tumors ◽  
Oncology Research ◽  
Urological Oncology ◽  
Metachronous Lesion

Background. Surgical treatment of solitary and oligometastatic metastases in renal cell carcinoma (RCC) is one of the treatment options for modern oncology.The objective of study to compare surgical outcomes in treatment of synchronous and metachronous solitary metastatic adrenal tumors in RCC.Materials and methods. The study included 93 patients with kidney cancer, from 1997 till 2018, who underwent surgical treatment in the urological oncology department of the P.A. Hertzen Moscow Oncology Research Institute. The 1st group is represented by 58 patients with RCC and synchronous secondary adrenal gland lesion, who underwent simultaneous surgery, consist of radical nephrectomy and adrenalectomy without subsequent adjuvant therapy. The 2nd group included 35 patients with metachronous solitary metastatic adrenal gland lesion who underwent surgical treatment.Results. The progression of disease to left adrenal gland was observed in 40 (43.0 %) cases, to the right – in 39 (41.9 %), both adrenal glands — 14 (15.1 %) cases. The median diameter of the adrenal tumors was 44 (4—170) mm, the most common in both groups were tumors less than 5 cm (58.1 %). The sensitivity of ultrasound in the diagnosis of adrenal tumors was 80.6 %, computed tomography – 93.5 %, adrenal biopsy – 73.9 %. The median of the observation time was 42 months (1st group — 24 months, 2nd group – the median was not achieved). The one-year survival of patients with a metachronous lesion of adrenal was 82.3 ± 76.6 % versus 52.8 ± 7.1 % in the synchronous lesion group, three-year survival was 79.2 ± 7.0 % versus 32.3 ± 7.6 % and five-year – 57.0 ± 10.0 % versus 16.2 ± 12.0 %, respectively. In multivariate analysis, only a metachronous lesion is a factor of favorable prognosis (p = 0.002).Conclusion. Surgical treatment for metachronous adrenal gland metastatic lesions is appropriate intervention and provides better patient survival rates compared to synchronous lesions.

Metastases of Renal Cell Carcinoma to the Contralateral Adrenal Gland Managed by Laparoscopic Adrenalectomy

2017 ◽  
Vol 8 (3) ◽  
pp. 326-330 ◽  
Author(s):  
R. B. Nerli ◽  
S. M. Patil ◽  
Amey Pathade ◽  
R. A. Patil ◽  
N. D. Pingale ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Adrenal Gland ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Laparoscopic Adrenalectomy

scholarly journals Renal Cell Carcinoma with Synchronous Metastasis to the Calcaneus and Metachronous Metastases to the Ovary and Gallbladder

2011 ◽  
Vol 2011 ◽  
pp. 1-4 ◽  
Author(s):  
Jasper Decoene ◽  
Filip Ameye ◽  
Evelyne Lerut ◽  
Raymond Oyen ◽  
Hein Van Poppel ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Surgical Treatment ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Review Of The Literature ◽  
Synchronous Metastasis ◽  
Renal Cell Carcinomas ◽  
Gallbladder Metastasis ◽  
Metachronous Metastases ◽  
Systemic Therapies

Renal cell carcinomas (RCCs) are known for their unpredictable metastatic pattern. We present the case of a 63-year-old woman who initially presented in 1992 with a metastasis in the left calcaneus that led to the discovery of RCC. In 1998, a new metastasis was found in the ovary. In 2008, the diagnosis of a gallbladder metastasis was made. All metastases were surgically removed; no additional systemic therapies were used. Aggressive surgical treatment can prolong the survival of patients with resectable metastases. Patterns of metastasis are discussed, and a brief review of the literature is given regarding each localization.

Multicentricity in Renal Cell Carcinoma: Can Primary Tumor Location Serve as a Co-Determinant of Surgical Treatment?

2002 ◽  
Vol 41 (3) ◽  
pp. 262-266 ◽  
Author(s):  
N. Melissourgos ◽  
K. Doumas ◽  
I. Messini ◽  
E. Papaliodi ◽  
N.G. Kastrinakis ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Surgical Treatment ◽  
Cell Carcinoma ◽  
Primary Tumor ◽  
Renal Cell ◽  
Tumor Location ◽  
Primary Tumor Location

Risk‐adjusted proposal for >60 months follow up after surgical treatment of organ‐confined renal cell carcinoma according to life expectancy

2018 ◽  
Vol 26 (3) ◽  
pp. 385-390 ◽  
Author(s):  
Sebastian K Frees ◽  
Mohammed M Kamal ◽  
Sebastian Nestler ◽  
Patrick MF Levien ◽  
Samir Bidnur ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Surgical Treatment ◽  
Life Expectancy ◽  
Cell Carcinoma ◽  
Renal Cell

scholarly journals Metastatic renal cell carcinoma of unknown primary site. Clinical follow-up

2020 ◽  
Vol 22 (3) ◽  
pp. 149-153
Author(s):  
N. A. Ognerubov ◽  
T. S. Antipova ◽  
G. E. Gumareva
Keyword(s):  
Computed Tomography ◽  
Renal Cell Carcinoma ◽  
Adrenal Gland ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Clear Cell ◽  
Cell Cancer ◽  
Primary Site ◽  
The Right

Renal cell cancer metastases without evidence of a primary tumor are extremely rare. These variants are usually showed as a spontaneous description of single clinical cases. Aim.This contribution is a clinical follow-up of synchronous renal cell cancer metastases of unknown primary site. Results.A 52-year-old patient U. with a history of increased blood pressure, up to 170/100 mmHg for the last 5 years, who had undergone many instrumental examinations, including ultrasound examination, because of this disease. The computed tomography of the abdomen showed a 4975 mm heterogeneous tumor in the right adrenal gland in October 2017. The combined positron emission and X-ray computed tomography showed a 795441 mm mass in the right adrenal gland, associated with elevated fluorodeoxyglucose metabolic activity SUVmax 7.25. Focal accumulation of the radiopharmaceutical SUVmax 4.31 in a 171124 mm mass was detected in the space of bifurcation in the mediastinum. The lytic lesion (1015 mm) was found in right superior L3 articular process. The patient underwent retroperitoneoscopic adrenalectomy and thoracoscopic removal of mediastinal tumor in November 2017 because of the oligometastatic nature of the process. The histological study identified clear-cell carcinoma with areas of papillary structure in the right adrenal gland. The immunohistochemical study showed carcinoma cells intensively expressing CD10, and some other cells RCC. The immune phenotype of the tumor was identified as clear-cell renal cell carcinoma. The immunohistological and immunohistochemical analysis reviled the metastases of the same variant of renal cell carcinoma in one of 9 lymph nodes. The patient was treated with pazopanib. The primary renal tumor was not detected during the dynamic observation, including the application of annual combined positron emission and X-ray computed tomography. The patient is alive without disease progression with a follow-up of 32 months. Conclusion.Metastases of clear-cell renal cell carcinoma, including adrenal gland, without evidence of a primary site are extremely rare. The main method of treatment is a combination of surgery and targeted therapy, providing long-term local control of the course of the disease.

scholarly journals Individual approach in choosing second-line targeted therapy for metastatic renal cell carcinoma

2018 ◽  
Vol 14 (2) ◽  
pp. 68-78 ◽  
Author(s):  
B. Ya. Alekseev ◽  
I. M. Shevchuk ◽  
A. D. Kaprin
Keyword(s):  
Renal Cell Carcinoma ◽  
Targeted Therapy ◽  
Surgical Treatment ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Optimal Dosage ◽  
Second Line ◽  
Newly Diagnosed ◽  
Disease Prognosis ◽  
Metastatic Rcc

Renal cell carcinoma (RCC) is one of the most common genitourinary malignancies worldwide. Approximately 25–30 % of newly diagnosed patients have metastatic RCC (mRCC), whereas in 20–30 % of cases, dissemination occurs after radical surgical treatment. The development of targeted and immunooncological agents in recent years significantly increased survival in patients with mRCC. However, clinicians faced a problem of choosing an optimal therapeutic regimen to achieve maximum effectiveness of the treatment. This article discusses the choice of second-line drugs for mRCC, advantages of axitinib and its optimal dosage, and efficacy of sunitinib depending on the disease prognosis.

Risk-based surveillance after surgical treatment of renal cell carcinoma

2018 ◽  
Vol 17 (2) ◽  
pp. e610
Author(s):  
P. Capogrosso ◽  
F. Muttin ◽  
A. Larcher ◽  
D. Sjoberg ◽  
E. Vertosick ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Surgical Treatment ◽  
Cell Carcinoma ◽  
Renal Cell

Metachronous Renal Cell Carcinoma Metastasis to the Contralateral Adrenal Gland

Urology ◽  
1998 ◽  
Vol 51 (4) ◽  
pp. 539-543 ◽  
Author(s):  
O.J Kessler ◽  
E Mukamel ◽  
R Weinstein ◽  
E Gayer ◽  
M Konichezky ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Adrenal Gland ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Renal Cell Carcinoma Metastasis ◽  
Carcinoma Metastasis

Urological neoplasia

2013 ◽  
pp. 235-394 ◽  
Author(s):  
John Reynard ◽  
Simon Brewster ◽  
Suzanne Biers
Keyword(s):  
Renal Cell Carcinoma ◽  
Surgical Treatment ◽  
Molecular Biology ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Radiological Assessment ◽  
Wilms Tumour ◽  
Renal Masses

Basic pathology and molecular biology 236 Wilms’ tumour and neuroblastoma 238 Radiological assessment of renal masses 242 Benign renal masses 244 Renal cell carcinoma: pathology, staging, and prognosis 246 Renal cell carcinoma: epidemiology and aetiology 250 Renal cell carcinoma: presentation and investigation 252 Renal cell carcinoma (localized): surgical treatment I ...

Sign in / Sign up

Export Citation Format

Share Document